Areas of interest include, but are not limited to: Classic antidiabetic, anti-obesity and cardioprotective effects Cardiovascular outcomes and mechanistic correlates Endothelial and vascular biology Myocardial metabolism and heart failure subtypes Novel renal and hepatoprotective actions Optimization and individualized use of existing GLP-1 receptor agonists Development of novel GLP-1 receptor agonists and multi-agonist (dual and triple) strategies Emerging extra-metabolic actions, including anti-inflammatory and neuroprotective effects Combination therapies, including co-formulations with insulin or SGLT2 inhibitors Innovative delivery systems, including non-injectable and implantable approaches Real-world comparative effectiveness, long-term safety, adherence and treatment durability This Collection welcomes original research, translational studies, and comprehensive reviews and meta-analyses that provide novel mechanistic insight or clinically relevant evidence to advance understanding of the expanding role of incretin-based therapies in cardiometabolic medicine
A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 requires careful specialist assessment before Wegovy use, due to precautionary warnings from animal studies
Het is goedgekeurd voor het gebruik bij babys en kinderen
Additional evidence pointing to a link between ceramides and activation of PKC is that mutation of a target serine in the kinase, S34, to alanine confers resistance to ceramide action
What side effects should I expect, and how can I manage them
Nucleosides (bottom) are made of a nitrogenous base, usually either a purine or pyrimidine, and a five-carbon carbohydrate, usually ribose
